Twist Bioscience Corp
TWST Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 26, 2026
$145.25
KIRA · Stoqly’s AI analyst, in plain words
- Twist Bioscience Corp had $377M of revenue in fiscal 2025, up 20.3% on the year before. Over five years, revenue changed +33.1% a year on average.
- Its operating margin was −36.2%, up 34.4 pts: of every 100 in sales, about −36 is left after running the business.
- Twist Bioscience Corp lost $77.7M in fiscal 2025.
- Free cash flow was −$75.6M in fiscal 2025, −20.1% of revenue.
Market cap
$9.1B
P/E
—
Revenue
$377M
Net income
−$77.7M
Free cash flow
−$75.6M
Operating margin
−36.2%
Twist Bioscience Corp in 30 seconds · fiscal 2025
Are sales growing?
+20.3%
Yes. Sales grew 20.3% last year.
Does it make a profit?
−20.6%
No. It lost money last year.
Does profit turn into cash?
−20.1%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Twist Bioscience Corp does
No business description yet.
- Fiscal year ends
- September 30, 2025
- Latest annual report
- 10-K · Nov 17, 2025
- Legal name
- Twist Bioscience Corp
- CIK
- 0001581280
Twist Bioscience Corp · TWST
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $132M | $204M | $245M | $313M | $377M |
| Revenue growth | 46.9% | 53.8% | 20.4% | 27.7% | 20.3% |
| Gross margin | 39.1% | 41.4% | 36.6% | 42.6% | 50.7% |
| Operating margin | −115.4% | −115.3% | −88.6% | −70.6% | −36.2% |
| Net income | −$152M | −$218M | −$205M | −$209M | −$77.7M |
| Net margin | −114.9% | −107.0% | −83.5% | −66.7% | −20.6% |
| Diluted EPS | −$3.15 | −$4.04 | −$3.60 | −$3.60 | −$1.30 |
| Cash | |||||
| Cash from operations | −$112M | −$124M | −$142M | −$64.1M | −$47.6M |
| Capital expenditure | $27.1M | $102M | $27.8M | $5.1M | $28.0M |
| Free cash flow | −$139M | −$226M | −$170M | −$69.2M | −$75.6M |
| FCF margin | −105.3% | −111.1% | −69.5% | −22.1% | −20.1% |
| Share count change | 23.1% | 11.7% | 5.6% | 2.0% | 3.1% |
| Debt and strength | |||||
| Cash and short-term investments | $478M | $505M | $336M | $276M | $232M |
| Debt incl. finance leases | $1.6M | $0.0M | — | — | — |
| Shareholders' equity | $581M | $789M | $623M | $473M | $473M |
| Current ratio | 8.7x | 6.6x | 5.8x | 4.9x | 3.6x |
| Interest coverage | −416.1x | −2,934.7x | −43,431.8x | −7,614.9x | — |
| Returns and quality | |||||
| Return on capital | −115.4% | −65.2% | — | — | — |
| Return on equity | −33.2% | −31.8% | −29.0% | −38.1% | −16.4% |
| Return on tangible equity | −28.2% | −33.8% | −42.4% | −56.0% | −20.6% |
| Piotroski F-score | 4 | 4 | 2 | 3 | 4 |
| Altman Z'' | 5.2 | 3.8 | 1.0 | −2.6 | −2.7 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$149M
10 insiders
Of sales under plans
81%
$121M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Twist Bioscience Corp · TWST
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $145.25 a share, the company is worth $9.1B.
Source: SEC EDGAR XBRL filings (CIK 0001581280). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.